×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NNVC – nanoviricides, inc. (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NNVC
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/23
06:41 am
nnvc
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape [Yahoo! Finance]
Low
Report
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape [Yahoo! Finance]
12/23
06:30 am
nnvc
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape
Low
Report
NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape
11/19
12:09 am
nnvc
NanoViricides, Inc. (NYSE: NNVC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
NanoViricides, Inc. (NYSE: NNVC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/15
06:50 am
nnvc
NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID [Yahoo! Finance]
Medium
Report
NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID [Yahoo! Finance]
11/15
06:30 am
nnvc
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
Medium
Report
NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID
11/8
11:07 pm
nnvc
NanoViricides, Inc. (NYSE: NNVC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
NanoViricides, Inc. (NYSE: NNVC) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
11/4
12:00 am
nnvc
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
Medium
Report
NanoViricides to Provide Corporate Update at the Spartan Capital Investors Conference 2024, Today at 9:45am
10/25
11:05 pm
nnvc
NanoViricides, Inc. (NYSE: NNVC) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
NanoViricides, Inc. (NYSE: NNVC) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/12
05:01 pm
nnvc
Form 8-K NANOVIRICIDES, INC. For: Dec 07
Low
Report
Form 8-K NANOVIRICIDES, INC. For: Dec 07
11/14
04:31 pm
nnvc
Form 10-Q NANOVIRICIDES, INC. For: Sep 30
Medium
Report
Form 10-Q NANOVIRICIDES, INC. For: Sep 30
10/15
04:45 pm
nnvc
Form DEF 14A NANOVIRICIDES, INC. For: Dec 07
Medium
Report
Form DEF 14A NANOVIRICIDES, INC. For: Dec 07
9/27
04:16 pm
nnvc
Form 10-K NANOVIRICIDES, INC. For: Jun 30
Medium
Report
Form 10-K NANOVIRICIDES, INC. For: Jun 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/24
Form SC 13G/A NANOVIRICIDES, INC. Filed by: SABBY MANAGEMENT, LLC
85.9%
1/24 Form 424B1 NANOVIRICIDES, INC. 44.4%
4/21 NanoViricides to Present COVID-19 and Shingles Drug Development Update at the Planet MicroCap Showcase Virtual Investor Conference 2020 on April 22nd 38.7%
1/30 NanoViricides Confirms It Has Been Working On A Treatment For The Novel Wuhan Coronavirus 37.7%
1/23 World Health Organization Accelerating Diagnostics, Vaccines, Therapeutics For Novel Coronavirus 35.7%
10/16 Form PRE 14A NANOVIRICIDES, INC. For: Oct 15 19.5%
2/10 Nanoviricides President Dr. Diwan Was Interviewed by The Varney Show on Fox Business News 17.1%
1/10 Technological Advancements Expand Biopharmaceuticals' Production Capabilities 16.2%
8/20 Form 3 NANOVIRICIDES, INC. For: Jun 02 Filed by: Day Mark D. 13.2%
10/25 NanoViricides, Inc., Builds Promising Pipeline Targeting a Multi-Billion Dollar Market for Herpes and Shingles 12.9%
1/24 Form 424B1 NANOVIRICIDES, INC. 44.4%
4/21 NanoViricides to Present COVID-19 and Shingles Drug Development Update at the Planet MicroCap Showcase Virtual Investor Conference 2020 on April 22nd 38.7%
1/30 NanoViricides Confirms It Has Been Working On A Treatment For The Novel Wuhan Coronavirus 37.7%
1/23 World Health Organization Accelerating Diagnostics, Vaccines, Therapeutics For Novel Coronavirus 35.7%
10/16 Form PRE 14A NANOVIRICIDES, INC. For: Oct 15 19.5%
2/10 Nanoviricides President Dr. Diwan Was Interviewed by The Varney Show on Fox Business News 17.1%
1/10 Technological Advancements Expand Biopharmaceuticals' Production Capabilities 16.2%
8/20 Form 3 NANOVIRICIDES, INC. For: Jun 02 Filed by: Day Mark D. 13.2%
10/25 NanoViricides, Inc., Builds Promising Pipeline Targeting a Multi-Billion Dollar Market for Herpes and Shingles 12.9%
TOP News Decliners
1/21
NanoViricides Prices $7.5 Million Underwritten Public Offering of Common Stock
-58.5%
1/28 Form 8-K NANOVIRICIDES, INC. For: Jan 27 -50.3%
2/1 The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO [Yahoo! Finance News] -30.5%
9/30 Form S-1 NANOVIRICIDES, INC. -23.8%
9/26 Form 8-K NANOVIRICIDES, INC. For: Sep 22 -21.6%
1/6 NanoViricides Receives Cash Infusion of $2.25 Million -19.1%
3/24 Form S-3 NANOVIRICIDES, INC. -15.9%
11/29 Form S-1 NANOVIRICIDES, INC. -15.0%
6/3 NanoViricides has Received Favorable FDA Comments on Its Pre-IND Application for the Lead Drug Candidate -13.8%
12/3 NanoViricides Founder Dr. Diwan Provides $2,000,000 Loan Commitment to the Company -11.2%
1/28 Form 8-K NANOVIRICIDES, INC. For: Jan 27 -50.3%
2/1 The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO [Yahoo! Finance News] -30.5%
9/30 Form S-1 NANOVIRICIDES, INC. -23.8%
9/26 Form 8-K NANOVIRICIDES, INC. For: Sep 22 -21.6%
1/6 NanoViricides Receives Cash Infusion of $2.25 Million -19.1%
3/24 Form S-3 NANOVIRICIDES, INC. -15.9%
11/29 Form S-1 NANOVIRICIDES, INC. -15.0%
6/3 NanoViricides has Received Favorable FDA Comments on Its Pre-IND Application for the Lead Drug Candidate -13.8%
12/3 NanoViricides Founder Dr. Diwan Provides $2,000,000 Loan Commitment to the Company -11.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: